pubmed-article:17453967 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:17453967 | lifeskim:mentions | umls-concept:C0038250 | lld:lifeskim |
pubmed-article:17453967 | lifeskim:mentions | umls-concept:C0079459 | lld:lifeskim |
pubmed-article:17453967 | lifeskim:mentions | umls-concept:C0332152 | lld:lifeskim |
pubmed-article:17453967 | lifeskim:mentions | umls-concept:C0206035 | lld:lifeskim |
pubmed-article:17453967 | lifeskim:mentions | umls-concept:C2698651 | lld:lifeskim |
pubmed-article:17453967 | lifeskim:mentions | umls-concept:C2926735 | lld:lifeskim |
pubmed-article:17453967 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:17453967 | pubmed:dateCreated | 2007-4-24 | lld:pubmed |
pubmed-article:17453967 | pubmed:abstractText | Harvesting of hemopoietic stem cells (HSC) from G-CSF-primed BM for autologous transplantation is an alternative to collection of unprimed BM or G-CSF-primed peripheral blood (PB). However, the optimum number of days of G-CSF administration for this purpose is unknown. We set out to determine whether cell yields could be optimized by varying the number of days of G-CSF administration prior to BM stem cell harvesting. | lld:pubmed |
pubmed-article:17453967 | pubmed:language | eng | lld:pubmed |
pubmed-article:17453967 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17453967 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:17453967 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17453967 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17453967 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:17453967 | pubmed:issn | 1465-3249 | lld:pubmed |
pubmed-article:17453967 | pubmed:author | pubmed-author:AndersonJJ | lld:pubmed |
pubmed-article:17453967 | pubmed:author | pubmed-author:LowenthalR... | lld:pubmed |
pubmed-article:17453967 | pubmed:author | pubmed-author:TuckDD | lld:pubmed |
pubmed-article:17453967 | pubmed:author | pubmed-author:NicholsonLL | lld:pubmed |
pubmed-article:17453967 | pubmed:author | pubmed-author:RaggS JSJ | lld:pubmed |
pubmed-article:17453967 | pubmed:author | pubmed-author:HarrupR ARA | lld:pubmed |
pubmed-article:17453967 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:17453967 | pubmed:volume | 9 | lld:pubmed |
pubmed-article:17453967 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:17453967 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:17453967 | pubmed:pagination | 158-64 | lld:pubmed |
pubmed-article:17453967 | pubmed:dateRevised | 2008-4-24 | lld:pubmed |
pubmed-article:17453967 | pubmed:meshHeading | pubmed-meshheading:17453967... | lld:pubmed |
pubmed-article:17453967 | pubmed:meshHeading | pubmed-meshheading:17453967... | lld:pubmed |
pubmed-article:17453967 | pubmed:meshHeading | pubmed-meshheading:17453967... | lld:pubmed |
pubmed-article:17453967 | pubmed:meshHeading | pubmed-meshheading:17453967... | lld:pubmed |
pubmed-article:17453967 | pubmed:meshHeading | pubmed-meshheading:17453967... | lld:pubmed |
pubmed-article:17453967 | pubmed:meshHeading | pubmed-meshheading:17453967... | lld:pubmed |
pubmed-article:17453967 | pubmed:meshHeading | pubmed-meshheading:17453967... | lld:pubmed |
pubmed-article:17453967 | pubmed:meshHeading | pubmed-meshheading:17453967... | lld:pubmed |
pubmed-article:17453967 | pubmed:meshHeading | pubmed-meshheading:17453967... | lld:pubmed |
pubmed-article:17453967 | pubmed:meshHeading | pubmed-meshheading:17453967... | lld:pubmed |
pubmed-article:17453967 | pubmed:meshHeading | pubmed-meshheading:17453967... | lld:pubmed |
pubmed-article:17453967 | pubmed:meshHeading | pubmed-meshheading:17453967... | lld:pubmed |
pubmed-article:17453967 | pubmed:meshHeading | pubmed-meshheading:17453967... | lld:pubmed |
pubmed-article:17453967 | pubmed:meshHeading | pubmed-meshheading:17453967... | lld:pubmed |
pubmed-article:17453967 | pubmed:year | 2007 | lld:pubmed |
pubmed-article:17453967 | pubmed:articleTitle | A randomized controlled clinical trial to determine the optimum duration of G-CSF priming prior to BM stem cell harvesting. | lld:pubmed |
pubmed-article:17453967 | pubmed:affiliation | Department of Haematology/Oncology, Royal Hobart Hospital. Hobart, Tasmania, Australia. R.M.Lowenthal@utas.edu.au | lld:pubmed |
pubmed-article:17453967 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:17453967 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
pubmed-article:17453967 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |